Ro, Lilly partnership creates volatility for Hims & Hers shares, says Leerink

The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is likely to cause volatility for Hims & Hers (HIMS) shares, Leerink tells investors in a research note. While Ro being first could result in Hims being boxed out from the DTC Zepbound channel, this data point could also be a positive for Hims & Hers, as the company may also pursue a similar strategy working with a manufacturer like Lilly or Novo Nordisk (NVO), the firm says, adding that this path could limit the regulatory uncertainty tied to relying on compounding. Leerink made no change to its Market Perform rating on Hims & Hers shares.